Table 3.
Treatment-emergent adverse events, n (%) | Total (N=302) |
---|---|
Headache | 12 (3.97) |
Nasopharyngitis | 11 (3.64) |
Nausea | 9 (2.98) |
Dizziness | 8 (2.65) |
Abdominal discomfort | 5 (1.66) |
Diarrhea | 4 (1.32) |
Insomnia | 4 (1.32) |
Dysphoria | 3 (0.99) |
Anxiety | 3 (0.99) |
Weight gain | 3 (0.99) |
Transaminase increased | 3 (0.99) |
Lassitude | 3 (0.99) |
Abbreviations: N, total sample size; n, number of occurrence of TEAEs; TEAE, treatment-emergent adverse event.